## Thomas A Buchholz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1813432/publications.pdf

Version: 2024-02-01

330 papers 30,158 citations

88 h-index 163 g-index

339 all docs 339 docs citations

times ranked

339

25667 citing authors

#	Article	IF	CITATIONS
1	Probability-based accounting for carbon in forests to consider wildfire and other stochastic events: synchronizing science, policy, and carbon offsets. Mitigation and Adaptation Strategies for Global Change, 2022, 27, 1.	1.0	2
2	Increasing the value of radiotherapy in breast cancer. Lancet Oncology, The, 2021, 22, 572-573.	5.1	4
3	When Biomass Electricity Demand Prompts Thinnings in Southern US Pine Plantations: A Forest Sector Greenhouse Gas Emissions Case Study. Frontiers in Forests and Global Change, 2021, 4, .	1.0	5
4	Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2021, 111, 360-370.	0.4	12
5	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncology, 2020, 6, 505.	3.4	51
6	Reply to A. Thomsen et al. Journal of Clinical Oncology, 2020, 38, 3577-3577.	0.8	1
7	Forest Carbon Resilience of Eastern Spruce Budworm (Choristoneura fumiferana) Salvage Harvesting in the Northeastern United States. Frontiers in Forests and Global Change, 2020, 3, .	1.0	8
8	Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Advances in Radiation Oncology, 2020, 5, 824-833.	0.6	7
9	Multidisciplinary Management of Locoregional Recurrent Breast Cancer. Journal of Clinical Oncology, 2020, 38, 2321-2328.	0.8	25
10	Economics of integrated harvests with biomass for energy in non-industrial forests in the northeastern US forest. Forest Policy and Economics, 2019, 109, 102023.	1.5	9
11	Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. Practical Radiation Oncology, 2019, 9, 402-409.	1.1	8
12	Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2019, 105, 174-182.	0.4	30
13	Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. International Journal of Radiation Oncology Biology Physics, 2019, 104, 574-581.	0.4	9
14	Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2019, 37, 423-438.	0.8	384
15	James Daniel Cox, MD, FASTRO, FACR. International Journal of Radiation Oncology Biology Physics, 2019, 103, 784-785.	0.4	O
16	Optimizing Patient Positioning to Reduce Variation in the Measurement of Breast Cancer-Related Lymphedema. Lymphatic Research and Biology, 2019, 17, 440-446.	0.5	5
17	Accelerated partial breast irradiation: Current status with a focus on clinical practice. Breast Journal, 2019, 25, 124-128.	0.4	14
18	A component of lobular carcinoma in clinically lymph nodeâ€"negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer. Advances in Radiation Oncology, 2018, 3, 252-257.	0.6	6

#	Article	IF	CITATIONS
19	Forest sector greenhouse gas emissions sensitivity to changes in forest management in Maine (USA). Forestry, 2018, 91, 526-538.	1.2	15
20	The role of postmastectomy radiotherapy in patients with stage II breast cancer. Cancer, 2018, 124, 450-452.	2.0	0
21	Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. Journal of Clinical Oncology, 2018, 36, 3495-3503.	0.8	54
22	Association of Transforming Growth Factor $\hat{l}^2$ Polymorphism $\hat{Ca}^2$ 509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer. JAMA Oncology, 2018, 4, 1751.	3.4	34
23	Reply to: Mastectomy skin flap thickness. European Journal of Surgical Oncology, 2018, 44, 1119-1120.	0.5	1
24	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. Journal of Clinical Oncology, 2017, 35, 1049-1060.	0.8	478
25	A Phase 2 Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 777-783.	0.4	30
26	Use of regional nodal irradiation and its association with survival for women with high-risk, early stage breast cancer: A National Cancer Database analysis. Advances in Radiation Oncology, 2017, 2, 291-300.	0.6	15
27	Quantitative Assessment of Breast Cosmetic Outcome After Whole-Breast Irradiation. International Journal of Radiation Oncology Biology Physics, 2017, 97, 894-902.	0.4	9
28	Greenhouse gas emissions of local wood pellet heat from northeastern US forests. Energy, 2017, 141, 483-491.	4.5	17
29	Using Discrete-Event Simulation to Promote Quality Improvement and Efficiency in a Radiation Oncology Treatment Center. Quality Management in Health Care, 2017, 26, 184-189.	0.4	5
30	Multidisciplinary international survey of post-operative radiation therapy practices after nipple-sparing or skin-sparing mastectomy. European Journal of Surgical Oncology, 2017, 43, 2036-2043.	0.5	16
31	A clinical perspective on regional nodal irradiation for breast cancer. Breast, 2017, 34, S85-S90.	0.9	14
32	Postoperative Radiation Therapy after Nipple-Sparing or Skin-Sparing Mastectomy: A Survey of European, North American, and South American Practices. Breast Journal, 2017, 23, 26-33.	0.4	8
33	Cost and Complications of Local Therapies for Early-Stage Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw178.	3.0	72
34	TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects. Oncogene, 2017, 36, 820-828.	2.6	37
35	Hospital Case Volume Is Associated With Improved Survival for Patients With Metastatic Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 491-496.	0.6	18
36	Longitudinal analysis of patientâ€reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated wholeâ€breast irradiation. Cancer, 2016, 122, 2886-2894.	2.0	29

3

#	Article	IF	CITATIONS
37	Complications After Mastectomy and Immediate Breast Reconstruction for Breast Cancer. Annals of Surgery, 2016, 263, 219-227.	2.1	151
38	Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer, 2016, 122, 917-928.	2.0	75
39	Final Reflections After 27 Years. Breast Diseases, 2016, 27, 248.	0.0	0
40	Forest biomass energy: assessing atmospheric carbon impacts by discounting future carbon flows. GCB Bioenergy, 2016, 8, 631-643.	2.5	30
41	Supply and Demand for Radiation Oncology in the United States: Updated Projections for 2015 to 2025. International Journal of Radiation Oncology Biology Physics, 2016, 96, 493-500.	0.4	83
42	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw026.	3.0	70
43	A global metaâ€analysis of forest bioenergy greenhouse gas emission accounting studies. GCB Bioenergy, 2016, 8, 281-289.	2.5	67
44	Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 637-644.	0.4	1
45	Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Research, 2016, 18, 97.	2.2	28
46	Postmastectomy Radiation Treatment Rates as a Quality Measure: An Opportunity for Compliance Through Collaboration. Annals of Surgical Oncology, 2016, 23, 2377-2379.	0.7	1
47	Trends in Local Therapy Utilization and Cost for Early-Stage Breast Cancer in Older Women: Implications for Payment and Policy Reform. International Journal of Radiation Oncology Biology Physics, 2016, 95, 605-616.	0.4	13
48	Practical Implications of the Publication ofÂConsensus Guidelines by the American SocietyÂfor Radiation Oncology: Accelerated Partial Breast Irradiation and the National Cancer Data Base. International Journal of Radiation Oncology Biology Physics, 2016, 94, 338-348.	0.4	21
49	Patterns of Local-Regional Management Following Neoadjuvant Chemotherapy in Breast Cancer: Results From ACOSOG Z1071 (Alliance). International Journal of Radiation Oncology Biology Physics, 2016, 94, 493-502.	0.4	33
50	Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes. Annals of Surgical Oncology, 2016, 23, 2385-2390.	0.7	34
51	Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal of Clinical Oncology, 2016, 34, 1689-1701.	0.8	243
52	Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costing. Brachytherapy, 2016, 15, 274-282.	0.2	37
53	Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncology, 2016, 2, 508.	3.4	103
54	Variations in Proton Therapy Coverage in the State of Texas: Defining Medical Necessity for a Safe and Effective Treatment. International Journal of Particle Therapy, 2016, 2, 499-508.	0.9	4

#	Article	IF	CITATIONS
55	MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Oncotarget, 2016, 7, 71660-71672.	0.8	31
56	Prognosis for patients with metastatic breast cancer who achieve a noâ€evidenceâ€ofâ€disease status after systemic or local therapy. Cancer, 2015, 121, 4324-4332.	2.0	34
57	Utilization of Surgery, Chemotherapy, Radiation Therapy, and Hospice at the End of Life for Patients Diagnosed With Metastatic Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 235-241.	0.6	14
58	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 242-247.	0.6	26
59	Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. Radiotherapy and Oncology, 2015, 115, 257-263.	0.3	105
60	Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. International Journal of Radiation Oncology Biology Physics, 2015, 93, 102-110.	0.4	3
61	Use of a tumour bed boost as part of radiotherapy for breast cancer. Lancet Oncology, The, 2015, 16, 5-6.	5.1	1
62	Proton partial breast irradiation in the supine position: Treatment description and reproducibility of a multibeam technique. Practical Radiation Oncology, 2015, 5, e283-e290.	1.1	8
63	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation. JAMA Oncology, 2015, 1, 931.	3.4	216
64	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Research and Treatment, 2015, 152, 407-416.	1.1	68
65	Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Research, 2015, 17, 42.	2.2	49
66	The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. SpringerPlus, 2015, 4, 36.	1.2	14
67	Influence of Neoadjuvant Chemotherapy on Radiotherapy for Breast Cancer. Annals of Surgical Oncology, 2015, 22, 1434-1440.	0.7	31
68	Sonography and Sonographically Guided Needle Biopsy of Internal Mammary Nodes in Staging of Patients With Breast Cancer. American Journal of Roentgenology, 2015, 205, 905-911.	1.0	22
69	Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy. Radiotherapy and Oncology, 2015, 117, 308-314.	0.3	23
70	Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy. Journal of the National Cancer Institute Monographs, 2015, 2015, 11-14.	0.9	37
71	Metastatic Tumor Volume and Extranodal Tumor Extension: Clinical Significance in Patients With Stage II Breast Cancer. Archives of Pathology and Laboratory Medicine, 2015, 139, 1288-1294.	1.2	11
72	Utilization and Outcomes of Breast Brachytherapy in Younger Women. International Journal of Radiation Oncology Biology Physics, 2015, 93, 91-101.	0.4	10

#	Article	IF	CITATIONS
73	Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. Journal of Geriatric Oncology, 2015, 6, 324-331.	0.5	36
74	Inhibition of <scp>EGFR</scp> or <scp>IGF</scp> â€IR signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit. Cancer Medicine, 2015, 4, 65-74.	1.3	8
<b>7</b> 5	Genetic variant rs16430 6bp > 0bp at the microRNAâ€binding site in <i>TYMS</i> and risk of sporadic breast cancer risk in nonâ€hispanic white women aged â‰ <b>\$</b> 5 years. Molecular Carcinogenesis, 2015, 54, 281-290.	1.3	15
76	Factors associated with radiation therapy incidents in a large academic institution. Practical Radiation Oncology, 2015, 5, 21-27.	1.1	20
77	Aldehyde Dehydrogenase1 Immunohistochemical Staining in Primary Breast Cancer Cells Independently Predicted Overall Survival But Did Not Correlate with the Presence of Circulating or Disseminated Tumors Cells. Journal of Cancer, 2014, 5, 360-367.	1.2	11
78	Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget, 2014, 5, 5076-5086.	0.8	49
79	Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial. Journal of Clinical Oncology, 2014, 32, 3600-3606.	0.8	323
80	Modeling economic and carbon consequences of a shift to wood-based energy in a rural â€~cluster'; a network analysis in southeast Alaska. Ecological Economics, 2014, 107, 287-298.	2.9	4
81	Mineral soil carbon fluxes in forests and implications for carbon balance assessments. GCB Bioenergy, 2014, 6, 305-311.	2.5	40
82	Uncertainty in projecting GHG emissions from bioenergy. Nature Climate Change, 2014, 4, 1045-1047.	8.1	26
83	Racial Disparities in Adoption of Axillary Sentinel Lymph Node Biopsy and Lymphedema Risk in Women With Breast Cancer. JAMA Surgery, 2014, 149, 788.	2.2	46
84	Poly (ADP-ribose) Polymerase Inhibitors in Cancer Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 90-100.	0.6	8
85	Increasing Use of Advanced Radiation Therapy Technologies in the Last 30 Days of Life Among Patients Dying As a Result of Cancer in the United States. Journal of Oncology Practice, 2014, 10, e269-e276.	2.5	13
86	Surgeon Influence on Use of Needle Biopsy in Patients With Breast Cancer: A National Medicare Study. Journal of Clinical Oncology, 2014, 32, 2206-2216.	0.8	24
87	Lobectomy, Sublobar Resection, and Stereotactic Ablative Radiotherapy for Early-Stage Non–Small Cell Lung Cancers in the Elderly. JAMA Surgery, 2014, 149, 1244.	2.2	227
88	Physician Variation in Management of Low-Risk Prostate Cancer. JAMA Internal Medicine, 2014, 174, 1450.	2.6	104
89	Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2014, 32, 2010-2017.	0.8	99
90	Benefit of Adjuvant Brachytherapy Versus External Beam Radiation for Early Breast Cancer: Impact of Patient Stratification on Breast Preservation. International Journal of Radiation Oncology Biology Physics, 2014, 88, 274-284.	0.4	32

#	Article	IF	CITATIONS
91	Survival of women with inflammatory breast cancer: a large population-based study. Annals of Oncology, 2014, 25, 1143-1151.	0.6	52
92	Simvastatin Radiosensitizes Differentiated and Stem-Like Breast Cancer Cell Lines and Is Associated With Improved Local Control in Inflammatory Breast Cancer Patients Treated With Postmastectomy Radiation. Stem Cells Translational Medicine, 2014, 3, 849-856.	1.6	69
93	Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2014, 32, 2255-2269.	0.8	661
94	Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: American Society of Clinical Oncology Endorsement of the Society of Surgical Oncology/American Society for Radiation Oncology Consensus Guideline. Journal of Clinical Oncology, 2014, 32, 1502-1506.	0.8	167
95	Trends and Variation in Use of Breast Reconstruction in Patients With Breast Cancer Undergoing Mastectomy in the United States. Journal of Clinical Oncology, 2014, 32, 919-926.	0.8	354
96	Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. SpringerPlus, 2014, 3, 166.	1.2	20
97	Statistical Modeling Approach to Quantitative Analysis of Interobserver Variability in Breast Contouring. International Journal of Radiation Oncology Biology Physics, 2014, 89, 214-221.	0.4	22
98	Therapeutic radiation dose delivered to the low axilla during whole breast radiation therapy in the prone position: Implications for targeting the undissected axilla. Practical Radiation Oncology, 2014, 4, 116-122.	1.1	7
99	Improved survival using intensityâ€modulated radiation therapy in head and neck cancers: A SEERâ€Medicare analysis. Cancer, 2014, 120, 702-710.	2.0	129
100	Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment. International Journal of Radiation Oncology Biology Physics, 2014, 89, 392-398.	0.4	126
101	Determinants of Practice Patterns and Quality Gaps in Lung Cancer Staging and Diagnosis. Chest, 2014, 145, 1097-1113.	0.4	32
102	Quality Gaps and Comparative Effectiveness in Lung Cancer Staging and Diagnosis. Chest, 2014, 145, 331-345.	0.4	56
103	Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy. Radiation Oncology, 2013, 8, 13.	1.2	30
104	Profitability of Willow Biomass Crops Affected by Incentive Programs. Bioenergy Research, 2013, 6, 53-64.	2.2	19
105	18F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1809-1816.	3.3	18
106	Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States. Cancer, 2013, 119, 1089-1097.	2.0	29
107	Modeling the profitability of power production from short-rotation woody crops in Sub-Saharan Africa. Biomass and Bioenergy, 2013, 59, 116-127.	2.9	3
108	Hypofractionated breast radiation: preferred standard of care?. Lancet Oncology, The, 2013, 14, 1032-1034.	5.1	15

#	Article	IF	Citations
109	Determinants of Patient Satisfaction During Receipt of Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, 148-152.	0.4	46
110	Other Primary Malignancies in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy. Annals of Surgical Oncology, 2013, 20, 1514-1521.	0.7	21
111	Accounting for Carbon Dioxide Emissions. Journal of Industrial Ecology, 2013, 17, 340-342.	2.8	16
112	Use of the LQ model with large fraction sizes results in underestimation of isoeffect doses. Radiotherapy and Oncology, 2013, 109, 21-25.	0.3	45
113	Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicities. Lung Cancer, 2013, 82, 252-259.	0.9	61
114	Rate of Radiation Therapy Events in a Large Academic Institution. Journal of the American College of Radiology, 2013, 10, 452-455.	0.9	6
115	Climate benefits from alternative energy uses of biomass plantations in Uganda. Biomass and Bioenergy, 2013, 59, 128-136.	2.9	18
116	Muddy Water? Variation in Reporting Receipt of Breast Cancer Radiation Therapy by Population-Based Tumor Registries. International Journal of Radiation Oncology Biology Physics, 2013, 86, 686-693.	0.4	61
117	Outcomes and Predictive Factors for Salvage Therapy After Local–Regional Recurrence Following Neoadjuvant Chemotherapy and Breast Conserving Therapy. Annals of Surgical Oncology, 2013, 20, 3430-3437.	0.7	6
118	Comparing land-use alternatives: Using the ecosystem services concept to define a multi-criteria decision analysis. Ecological Economics, 2013, 93, 128-136.	2.9	124
119	Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer. Journal of Clinical Oncology, 2013, 31, 4222-4228.	0.8	207
120	Regional variation in forest harvest regimes in the northeastern United States. Ecological Applications, 2013, 23, 515-522.	1.8	50
121	Accelerated partial-breast irradiation using intensity-modulated proton radiotherapy: do uncertainties outweigh potential benefits?. British Journal of Radiology, 2013, 86, 20130176.	1.0	23
122	Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer. Annals of Oncology, 2013, 24, 1999-2004.	0.6	65
123	Breast Cancer Multifocality and Multicentricity and Locoregional Recurrence. Oncologist, 2013, 18, 1167-1173.	1.9	62
124	Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer. JAMA - Journal of the American Medical Association, 2013, 310, 1455.	3.8	1,153
125	Reply to P.G. Tsoutsou et al. Journal of Clinical Oncology, 2013, 31, 648-649.	0.8	0
126	Radiation Treatments After Breast-Conserving Therapy for Elderly Patients. Journal of Clinical Oncology, 2013, 31, 2367-2368.	0.8	20

#	Article	IF	Citations
127	Reply to P.G. Tsoutsou et al and O. Kaidar-Person et al. Journal of Clinical Oncology, 2013, 31, 4573-4573.	0.8	O
128	Evaluating the impact of patient, tumor, and treatment characteristics on the development of jaw complications in patients treated for oral cancers: A SEER-Medicare analysis. Head and Neck, 2013, 35, 1599-1605.	0.9	52
129	Use of Radiation Therapy in the Last 30 Days of Life Among a Large Population-Based Cohort of Elderly Patients in the United States. Journal of Clinical Oncology, 2013, 31, 80-87.	0.8	133
130	Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast-Conserving Therapy. Annals of Surgery, 2013, 257, 173-179.	2.1	83
131	Anthracycline Regimen Adherence in Older Patients with Early Breast Cancer. Oncologist, 2012, 17, 303-311.	1.9	23
132	Identifying factors that impact survival among women with inflammatory breast cancer. Annals of Oncology, 2012, 23, 870-875.	0.6	42
133	The Value of Ultrasound in Detecting Extra-Axillary Regional Node Involvement in Patients With Advanced Breast Cancer. Oncologist, 2012, 17, 1402-1408.	1.9	24
134	A Population-Based Study of the Quality of Care in the Diagnosis of Large (≥5 cm) Soft Tissue Sarcomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 455-461.	0.6	7
135	Considerations of Project Scale and Sustainability of Modern Bioenergy Systems in Uganda. Journal of Sustainable Forestry, 2012, 31, 154-173.	0.6	10
136	Power from wood gasifiers in Uganda: a 250 kW and 10 kW case study. Proceedings of Institution of Civil Engineers: Energy, 2012, 165, 181-196.	0.5	17
137	Nomogram to Predict the Benefit of Radiation for Older Patients With Breast Cancer Treated With Conservative Surgery. Journal of Clinical Oncology, 2012, 30, 2837-2843.	0.8	86
138	Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-Medicare. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 800-809.	1.1	99
139	Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection. Annals of Surgery, 2012, 256, 428-436.	2.1	84
140	Association Between Treatment With Brachytherapy vs Whole-Breast Irradiation and Subsequent Mastectomy, Complications, and Survival Among Older Women With Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1827-37.	3.8	169
141	Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist, 2012, 17, 891-899.	1.9	127
142	MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Investigational New Drugs, 2012, 30, 2113-2120.	1.2	73
143	Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncology, The, 2012, 13, e270-e276.	5.1	28
144	Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Research, 2012, 14, R72.	2.2	96

#	Article	IF	Citations
145	Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Research, 2012, 14, R82.	2.2	44
146	Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Research, 2012, 14, R83.	2.2	118
147	Impact of Body Mass Index on Survival Outcome Among Women With Early Stage Triple-Negative Breast Cancer. Clinical Breast Cancer, 2012, 12, 364-372.	1.1	56
148	Radiation Therapy After Breast-Conserving Surgery: Does Hospital Surgical Volume Matter? A Population-Based Study in Taiwan. International Journal of Radiation Oncology Biology Physics, 2012, 82, 43-50.	0.4	5
149	Cardiac Motion During Deep-Inspiration Breath-Hold: Implications for Breast Cancer Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 708-714.	0.4	47
150	Topical Hyaluronic Acid vs. Standard of Care for the Prevention of Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer: Single-Blind Randomized Phase III Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1089-1094.	0.4	65
151	Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients WithÂlnflammatory Breast Cancer Influences RadiationÂTreatment Field Designs. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1381-1386.	0.4	42
152	Brachytherapy vs Whole-Breast Irradiation: Trial by Data. International Journal of Radiation Oncology Biology Physics, 2012, 83, 1078-1080.	0.4	0
153	Comparative Effectiveness of 5 Treatment Strategies for Early-Stage Non-Small Cell Lung Cancer in the Elderly. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1060-1070.	0.4	246
154	Semiquantitative Analysis of Maximum Standardized Uptake Values of Regional Lymph Nodes in Inflammatory Breast Cancer. Academic Radiology, 2012, 19, 535-541.	1.3	13
155	Management of adenoid cystic carcinoma of the breast:Âa Rare Cancer Network Study. Breast Diseases, 2012, 23, 339-341.	0.0	0
156	Lessons from a Woman Who Beat the Odds. Breast Diseases, 2012, 23, 120.	0.0	0
157	Current clinical coverage of Radiation Therapy Oncology Group-defined target volumes for postmastectomy radiation therapy. Practical Radiation Oncology, 2012, 2, 201-209.	1.1	30
158	Impact of Postmastectomy Radiation on Locoregional Recurrence in Breast Cancer Patients With 1-3 Positive Lymph Nodes Treated With Modern Systemic Therapy. Breast Diseases, 2012, 23, 355-357.	0.0	1
159	Effectiveness of radiation for prevention of mastectomy in older breast cancer patients treated with conservative surgery. Cancer, 2012, 118, 4642-4651.	2.0	34
160	Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells Through WNT/βâ€Catenin Signaling. Stem Cells, 2012, 30, 2366-2377.	1.4	100
161	Oncology Scan – February 1, 2012. International Journal of Radiation Oncology Biology Physics, 2012, 82, 505-507.	0.4	4
162	Association Between Age at Diagnosis and Disease-Specific Mortality Among Postmenopausal Women With Hormone Receptor–Positive Breast Cancer. Breast Diseases, 2012, 23, 242-243.	0.0	0

#	Article	IF	Citations
163	Outcomes of positron emission tomography–staged clinical N3 breast cancer treated with neoadjuvant chemotherapy, surgery, and radiotherapy. Breast Diseases, 2012, 23, 135-136.	0.0	O
164	Multifocality and multicentricity in breast cancer and survival outcomes. Annals of Oncology, 2012, 23, 3063-3069.	0.6	72
165	Evaluation of the MD Anderson Prognostic Index for Local-Regional Recurrence After Breast Conserving Therapy in Patients Receiving Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2012, 19, 901-907.	0.7	47
166	The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer, 2012, 118, 2780-2786.	2.0	24
167	Incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer. Cancer, 2012, 118, 4652-4659.	2.0	64
168	Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer. Cancer, 2012, 118, 4936-4943.	2.0	25
169	Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer. Cancer, 2012, 118, 6287-6296.	2.0	33
170	Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Research and Treatment, 2012, 134, 495-510.	1.1	56
171	Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case–control study. Breast Cancer Research and Treatment, 2012, 132, 1147-1155.	1.1	8
172	Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers. Cancer, 2012, 118, 1498-1506.	2.0	69
173	Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer. Cancer, 2012, 118, 1507-1514.	2.0	9
174	Radiation Therapy for Inflammatory Breast Cancer. , 2012, , 75-84.		1
175	How Does Biology Affect Local Therapy Decisions?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 56-57.	1.8	0
176	Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes. Breast Diseases, 2011, 22, 393-394.	0.0	0
177	Systematic review of the effect of external beam radiation therapy to the breast on axillary recurrence after negative sentinel lymph node biopsy. Breast Diseases, 2011, 22, 306-307.	0.0	0
178	Automating RTOG-defined target volumes for postmastectomy radiation therapy. Practical Radiation Oncology, 2011, 1, 97-104.	1.1	4
179	Local-Regional Recurrence With and Without Radiation Therapy After Neoadjuvant Chemotherapy and Mastectomy for Clinically Staged T3NO Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 81, 782-787.	0.4	64
180	Radiotherapy and survival in breast cancer. Lancet, The, 2011, 378, 1680-1682.	6.3	15

#	Article	IF	CITATIONS
181	A Multidisciplinary Protocol for Planned Skin-Preserving Delayed Breast Reconstruction for Patients with Locally Advanced Breast Cancer Requiring Postmastectomy Radiation Therapy: 3-Year Follow-Up. Plastic and Reconstructive Surgery, 2011, 127, 2154-2166.	0.7	94
182	Breast Conservation Therapy in the 21st Century. Breast Journal, 2011, 17, 445-447.	0.4	0
183	Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Annals of Surgical Oncology, 2011, 18, 2407-2412.	0.7	113
184	Improving the Profitability of Willow Cropsâ€"Identifying Opportunities with a Crop Budget Model. Bioenergy Research, 2011, 4, 85-95.	2.2	80
185	Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early. Cancer, 2011, 117, 1819-1826.	2.0	121
186	Impact of evidenceâ€based clinical guidelines on the adoption of postmastectomy radiation in older women. Cancer, 2011, 117, 4595-4605.	2.0	41
187	Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer, 2011, 117, 5476-5484.	2.0	61
188	Long-Term Outcomes in Patients With Isolated Supraclavicular Nodal Recurrence After Mastectomy and Doxorubicin-Based Chemotherapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1453-1457.	0.4	20
189	External-Beam Accelerated Partial Breast Irradiation Using Multiple Proton Beam Configurations. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1464-1472.	0.4	43
190	Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Annals of Oncology, 2011, 22, 2394-2402.	0.6	19
191	Improvement in Breast Cancer Outcomes Over Time: Are Older Women Missing Out?. Journal of Clinical Oncology, 2011, 29, 4647-4653.	0.8	131
192	MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells. Clinical Cancer Research, 2011, 17, 5638-5648.	3.2	196
193	Positive Sentinel Nodes Without Axillary Dissection: Implications for the Radiation Oncologist. Journal of Clinical Oncology, 2011, 29, 4479-4481.	0.8	122
194	Nodal Status and Clinical Outcomes in a Large Cohort of Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2011, 29, 2628-2634.	0.8	128
195	Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist, 2011, 16, 1675-1683.	1.9	86
196	Adoption of Intensity-Modulated Radiation Therapy for Breast Cancer in the United States. Journal of the National Cancer Institute, 2011, 103, 798-809.	3.0	128
197	Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current American Joint Committee on Cancer Staging System. Journal of Clinical Oncology, 2011, 29, 4654-4661.	0.8	92
198	Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2011, 29, 1956-1962.	0.8	140

#	Article	IF	Citations
199	Brachytherapy for Accelerated Partial-Breast Irradiation: A Rapidly Emerging Technology in Breast Cancer Care. Journal of Clinical Oncology, 2011, 29, 157-165.	0.8	64
200	Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy. Annals of Surgical Oncology, 2010, 17, 2899-2908.	0.7	74
201	Clinically Apparent Internal Mammary Nodal Metastasis in Patients With Advanced Breast Cancer: Incidence and Local Control. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1113-1119.	0.4	51
202	How Improved Local-Regional Therapy Impacts Survival. Current Breast Cancer Reports, 2010, 2, 83-89.	0.5	1
203	The functional promoter polymorphism (â '842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55Ayears and younger. Breast Cancer Research and Treatment, 2010, 122, 243-249.	1.1	35
204	Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Research and Treatment, 2010, 123, 597-605.	1.1	8
205	Inflammatory Breast Cancer: The Disease, the Biology, the Treatment. Ca-A Cancer Journal for Clinicians, 2010, 60, 351-375.	157.7	298
206	Racial disparities in the use of radiotherapy after breastâ€conserving surgery: A national Medicare study. Cancer, 2010, 116, 734-741.	2.0	82
207	Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy. Cancer, 2010, 116, 3084-3092.	2.0	31
208	Overcoming radiation resistance in inflammatory breast cancer. Cancer, 2010, 116, 2840-2845.	2.0	25
209	Potential of distributed wood-based biopower systems serving basic electricity needs in rural Uganda. Energy for Sustainable Development, 2010, 14, 56-61.	2.0	46
210	Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bNO Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1296-1302.	0.4	79
211	Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast Journal, 2010, 16, 529-532.	0.4	24
212	The Future of Radiation Oncology in the United States From 2010 to 2020: Will Supply Keep Pace With Demand?. Journal of Clinical Oncology, 2010, 28, 5160-5165.	0.8	130
213	American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3784-3796.	0.8	655
214	Mesenchymal Stem Cells Promote Mammosphere Formation and Decrease E-Cadherin in Normal and Malignant Breast Cells. PLoS ONE, 2010, 5, e12180.	1.1	148
215	Modeling heliotropic tree growth in hardwood tree speciesâ€"A case study on Maesopsis eminii. Forest Ecology and Management, 2010, 260, 1656-1663.	1.4	3
216	Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and post-mastectomy radiation. Radiotherapy and Oncology, 2010, 95, 312-316.	0.3	21

#	Article	IF	Citations
217	Whole Breast Radiotherapy. , 2010, , 813-827.		O
218	High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller. Journal of Clinical Oncology, 2009, 27, 5700-5706.	0.8	404
219	Accelerated Partial Breast Irradiation Consensus Statement from the American Society for Radiation Oncology (ASTRO). Journal of the American College of Surgeons, 2009, 209, 269-277.	0.2	108
220	Identifying the "sentinel lymph nodes―for arm drainage as a strategy for minimizing the lymphedema risk after breast cancer therapy. Breast Cancer Research and Treatment, 2009, 116, 539-541.	1,1	3
221	Postsurgical radiation therapy in patients with complete response to neoadjuvant chemotherapy. Current Breast Cancer Reports, 2009, 1, 86-89.	0.5	0
222	Effects of Variable Placement of Superior Tangential/Supraclavicular Match Line on Dosimetric Coverage of Level III Axilla/Axillary Apex in Patients Treated With Breast and Supraclavicular Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 370-374.	0.4	14
223	Multi Criteria Analysis for bioenergy systems assessments. Energy Policy, 2009, 37, 484-495.	4.2	193
224	Sustainability criteria for bioenergy systems: results from an expert survey. Journal of Cleaner Production, 2009, 17, S86-S98.	4.6	183
225	Automatic Segmentation of Whole Breast Using Atlas Approach and Deformable Image Registration. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1493-1500.	0.4	102
226	Baseline Utilization of Breast Radiotherapy Before Institution of the Medicare Practice Quality Reporting Initiative. International Journal of Radiation Oncology Biology Physics, 2009, 74, 1506-1512.	0.4	23
227	Variability of Target and Normal Structure Delineation for Breast Cancer Radiotherapy: An RTOG Multi-Institutional and Multiobserver Study. International Journal of Radiation Oncology Biology Physics, 2009, 73, 944-951.	0.4	321
228	Accelerated Partial Breast Irradiation Consensus Statement From the American Society for Radiation Oncology (ASTRO). International Journal of Radiation Oncology Biology Physics, 2009, 74, 987-1001.	0.4	797
229	Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study. Journal of Clinical Oncology, 2009, 27, 2007-2014.	0.8	378
230	Radiation Therapy for Early-Stage Breast Cancer after Breast-Conserving Surgery. New England Journal of Medicine, 2009, 360, 63-70.	13.9	113
231	Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation. Journal of Clinical Oncology, 2009, 27, 2758-2765.	0.8	1,486
232	Genetic variants in the H2AFX promoter region are associated with risk of sporadic breast cancer in non-Hispanic white women aged â‰\$5 years. Breast Cancer Research and Treatment, 2008, 110, 357-366.	1.1	24
233	Completion of adjuvant radiation therapy among women with breast cancer. Cancer, 2008, 113, 22-29.	2.0	60
234	Use of Postmastectomy Radiotherapy in Older Women. International Journal of Radiation Oncology Biology Physics, 2008, 71, 98-106.	0.4	41

#	Article	IF	CITATIONS
235	Risk of Subclinical Micrometastatic Disease in the Supraclavicular Nodal Bed According to the Anatomic Distribution in Patients With Advanced Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 71, 435-440.	0.4	38
236	Radiation Use and Long-Term Survival in Breast Cancer Patients With T1, T2 Primary Tumors and One to Three Positive Axillary Lymph Nodes. International Journal of Radiation Oncology Biology Physics, 2008, 71, 1022-1027.	0.4	29
237	Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 474-484.	0.4	130
238	The Role of Locoregional Therapy in Inflammatory Breast Cancer. Seminars in Oncology, 2008, 35, 78-86.	0.8	33
239	Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant Therapy. Journal of Clinical Oncology, 2008, 26, 246-252.	0.8	164
240	Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer: A National Cancer Institute Conference. Journal of Clinical Oncology, 2008, 26, 791-797.	0.8	206
241	Staging of Breast Cancer in the Neoadjuvant Setting. Cancer Research, 2008, 68, 6477-6481.	0.4	38
242	Trends for Inflammatory Breast Cancer: Is Survival Improving?. Oncologist, 2007, 12, 904-912.	1.9	106
243	Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clinical Cancer Research. 2007. 13. 228-233.	3.2	434
244	Multileaf field-in-field forward-planned intensity-modulated dose compensation for whole-breast irradiation is associated with reduced contralateral breast dose: A phantom model comparison. Radiotherapy and Oncology, 2007, 82, 324-328.	0.3	54
245	WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 618-623.	3.3	599
246	Wnt/ $\hat{l}^2$ -catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. Journal of Cell Science, 2007, 120, 468-477.	1.2	170
247	Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer, 2007, 110, 723-730.	2.0	145
248	Inflammatory breast cancer (IBC) and patterns of recurrence. Cancer, 2007, 110, 1436-1444.	2.0	194
249	A participatory systems approach to modeling social, economic, and ecological components of bioenergy. Energy Policy, 2007, 35, 6084-6094.	4.2	107
250	Postmastectomy Radiation Improves the Outcome of Patients With Locally Advanced Breast Cancer Who Achieve a Pathologic Complete Response to Neoadjuvant Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1004-1009.	0.4	229
251	Effect of Postmastectomy Radiotherapy in Patients <35 Years Old With Stage II-III Breast Cancer Treated With Doxorubicin-Based Neoadjuvant Chemotherapy and Mastectomy. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1478-1483.	0.4	45
252	Role for Intraoperative Margin Assessment in Patients Undergoing Breast-Conserving Surgery. Annals of Surgical Oncology, 2007, 14, 1458-1471.	0.7	229

#	Article	IF	Citations
253	DCIS of the breast: Solving the puzzle. Women's Oncology Review, 2007, 6, 83-84.	0.0	O
254	Radiation after breast conservative surgery or after mastectomy reduces local recurrence and improves overall survival in breast cancer. Women's Oncology Review, 2007, 6, 67-69.	0.0	3
255	Inflammatory Breast Cancer: Current Concepts in Local Management. Breast Disease, 2006, 22, 75-83.	0.4	21
256	Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1155-1160.	0.4	13
257	The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. International Journal of Radiation Oncology Biology Physics, 2006, 66, 76-82.	0.4	236
258	Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. International Journal of Radiation Oncology Biology Physics, 2006, 66, 352-357.	0.4	77
259	Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. International Journal of Radiation Oncology Biology Physics, 2006, 66, 358-364.	0.4	77
260	Locoregional Control of Clinically Diagnosed Multifocal or Multicentric Breast Cancer After Neoadjuvant Chemotherapy and Locoregional Therapy. Journal of Clinical Oncology, 2006, 24, 4971-4975.	0.8	68
261	Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors. Journal of Clinical Oncology, 2006, 24, 1037-1044.	0.8	514
262	Effectiveness of Radiation Therapy in Older Women With Ductal Carcinoma In Situ. Journal of the National Cancer Institute, 2006, 98, 1302-1310.	3.0	76
263	The Use of Radiation As a Component of Breast Conservation Therapy in National Comprehensive Cancer Network Centers. Journal of Clinical Oncology, 2006, 24, 361-369.	0.8	80
264	Postmastectomy Radiation as a Component of the Multidisciplinary Management of Breast Cancer Patients. Cancer Journal (Sudbury, Mass), 2005, 11, 198-200.	1.0	0
265	Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Women's Oncology Review, 2005, 5, 53-55.	0.0	O
266	Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 62, 351-357.	0.4	114
267	Clinical investigation: Regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1508-1513.	0.4	92
268	Is partial breast irradiation a step forward or backward?. Seminars in Radiation Oncology, 2005, 15, 69-75.	1.0	18
269	Breast conservation after neoadjuvant chemotherapy. Cancer, 2005, 103, 689-695.	2.0	130
270	Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer, 2005, 103, 1323-1329.	2.0	38

#	Article	IF	CITATIONS
271	Improving local control with breast-conserving therapy. Cancer, 2005, 104, 20-29.	2.0	109
272	Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer, 2005, 104, 676-681.	2.0	50
273	Cardiac Morbidity of Adjuvant Radiotherapy for Breast Cancer. Journal of Clinical Oncology, 2005, 23, 7475-7482.	0.8	204
274	Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal of Clinical Oncology, 2005, 23, 3676-3685.	0.8	1,076
275	The Nuclear Transcription Factor labeled Pathway Correlates with Pathologic Complete Response to Doxorubicin-Based Neoadjuvant Chemotherapy in Human Breast Cancer. Clinical Cancer Research, 2005, 11, 8398-8402.	3.2	91
276	Factors Predictive of Distant Metastases in Patients With Breast Cancer Who Have a Pathologic Complete Response After Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 2005, 23, 7098-7104.	0.8	98
277	Risk of Cardiac Death After Adjuvant Radiotherapy for Breast Cancer. Journal of the National Cancer Institute, 2005, 97, 419-424.	3.0	503
278	Site of primary tumor has a prognostic role in operable breast cancer: The International Breast Cancer Study Group experience. Women's Oncology Review, 2005, 5, 117-119.	0.0	0
279	Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Women's Oncology Review, 2005, 5, 53-55.	0.0	0
280	Postmastectomy Radiation Improves Local-Regional Control and Survival for Selected Patients With Locally Advanced Breast Cancer Treated With Neoadjuvant Chemotherapy and Mastectomy. Journal of Clinical Oncology, 2004, 22, 4691-4699.	0.8	264
281	Breast Conservation After Neoadjuvant Chemotherapy: The M.D. Anderson Cancer Center Experience. Journal of Clinical Oncology, 2004, 22, 2303-2312.	0.8	359
282	Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1074-1079.	0.4	29
283	Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1337-1342.	0.4	28
284	A Ser49Cys variant in the ataxia telangiectasia, mutated, gene that is more common in patients with breast carcinoma compared with population controls. Cancer, 2004, 100, 1345-1351.	2.0	41
285	T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 59, 138-145.	0.4	70
286	Delayed-Immediate Breast Reconstruction. Plastic and Reconstructive Surgery, 2004, 113, 1617-1628.	0.7	335
287	Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer, 2003, 97, 926-933.	2.0	206
288	Neoadjuvant chemotherapy for breast carcinoma. Cancer, 2003, 98, 1150-1160.	2.0	105

#	Article	IF	Citations
289	Outcome of treatment for breast cancer patients with chest wall recurrence according to initial stage: Implications for post-mastectomy radiation therapy. International Journal of Radiation Oncology Biology Physics, 2003, 57, 128-135.	0.4	29
290	Partial breast irradiationâ€"is it ready for prime time?. International Journal of Radiation Oncology Biology Physics, 2003, 57, 1214-1216.	0.4	13
291	Locoregional recurrence after doxorubicin-based chemotherapy and postmastectomy: Implications for breast cancer patients with early-stage disease and predictors for recurrence after postmastectomy radiation. International Journal of Radiation Oncology Biology Physics, 2003, 57, 336-344.	0.4	87
292	Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer. Surgical Clinics of North America, 2003, 83, 911-930.	0.5	19
293	Chest Wall Recurrence After Mastectomy Does Not Always Portend a Dismal Outcome. Annals of Surgical Oncology, 2003, 10, 628-634.	0.7	76
294	Chemotherapy-Induced Apoptosis and Bcl-2 Levels Correlate with Breast Cancer Response to Chemotherapy. Cancer Journal (Sudbury, Mass ), 2003, 9, 33-41.	1.0	122
295	Controversies Regarding the Use of Radiation After Mastectomy in Breast Cancer. Oncologist, 2002, 7, 539-546.	1.9	82
296	Global Gene Expression Changes During Neoadjuvant Chemotherapy for Human Breast Cancer. Cancer Journal (Sudbury, Mass), 2002, 8, 461-468.	1.0	91
297	Predictors of Local-Regional Recurrence After Neoadjuvant Chemotherapy and Mastectomy Without Radiation. Journal of Clinical Oncology, 2002, 20, 17-23.	0.8	162
298	Molecular biology and genetics of breast cancer development: A clinical perspective. Seminars in Radiation Oncology, 2002, 12, 285-295.	1.0	30
299	Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. International Journal of Cancer, 2002, 97, 557-561.	2.3	81
300	Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Annals of Surgical Oncology, 2002, 9, 256-265.	0.7	112
301	Long-term complications associated with breast-conservation surgery and radiotherapy. Annals of Surgical Oncology, 2002, 9, 543-549.	0.7	223
302	Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 53, 880-888.	0.4	92
303	Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. International Journal of Radiation Oncology Biology Physics, 2002, 53, 1225-1233.	0.4	52
304	A prospective trial of preoperative chemotherapy in resectable breast cancer: Predictors of breast-conservation therapy feasibility., 2002, 9, 228.		14
305	Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy., 2002, 9, 256.		5
306	Long-term complications associated with breast-conservation surgery and radiotherapy. , 2002, 9, 543.		12

#	Article	IF	CITATIONS
307	Impact of Systemic Treatment on Local Control for Patients With Lymph Node–Negative Breast Cancer Treated With Breast-Conservation Therapy. Journal of Clinical Oncology, 2001, 19, 2240-2246.	0.8	99
308	Verification of tangential breast treatment dose calculations in a commercial 3D treatment planning system. Journal of Applied Clinical Medical Physics, 2001, 2, 73-84.	0.8	7
309	Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases. Annals of Surgical Oncology, 2001, 8, 425-431.	0.7	117
310	Radiation-induced chromatid breaks as a predictor of breast cancer risk. International Journal of Radiation Oncology Biology Physics, 2001, 49, 533-537.	0.4	39
311	The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. International Journal of Radiation Oncology Biology Physics, 2001, 50, 735-742.	0.4	165
312	Relationship of sentinel and axillary level I–II lymph nodes to tangential fields used in breast irradiation. International Journal of Radiation Oncology Biology Physics, 2001, 51, 671-678.	0.4	150
313	A case-control study of unilateral and bilateral breast carcinoma patients. Cancer, 2001, 91, 1845-1853.	2.0	76
314	Breast conservation therapy as a treatment option for the elderly. Cancer, 2001, 92, 1092-1100.	2.0	50
315	Recursive partitioning analysis of locoregional recurrence patterns following mastectomy: implications for adjuvant irradiation. International Journal of Radiation Oncology Biology Physics, 2001, 50, 397-403.	0.4	82
316	Verification of tangential breast treatment dose calculations in a commercial 3D treatment planning system. Journal of Applied Clinical Medical Physics, 2001, 2, 73.	0.8	9
317	Feasibility of Breast Preservation in the Treatment of Occult Primary Carcinoma Presenting With Axillary Metastases., 2001, 8, 425.		1
318	Internal mammary lymph nodes: to treat or not to treat. International Journal of Radiation Oncology Biology Physics, 2000, 46, 801-803.	0.4	35
319	Carcinoma of the male breast. Current Treatment Options in Oncology, 2000, 1, 221-227.	1.3	11
320	Prognostic Implications of Pathological Lymph Node Status After Preoperative Chemotherapy for Operable T3NOMO Breast Cancer. Annals of Surgical Oncology, 2000, 7, 435-440.	0.7	26
321	Ductal Carcinoma-In-Situ: Long-Term Results of Breast-Conserving Therapy. Annals of Surgical Oncology, 2000, 7, 656-664.	0.7	38
322	Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation. Journal of Clinical Oncology, 2000, 18, 2817-2827.	0.8	367
323	Frequency of First Metastatic Events in Breast Cancer: Implications for Sequencing of Systemic and Local-Regional Treatment. Journal of Clinical Oncology, 1999, 17, 2649-2649.	0.8	43
324	Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control?. International Journal of Radiation Oncology Biology Physics, 1999, 44, 105-112.	0.4	37

#	ARTICLE	IF	CITATIONS
325	Feasibility of Breast Conservation Therapy in Metachronous or Synchronous Bilateral Breast Cancer. Annals of Surgical Oncology, 1999, 6, 102-108.	0.7	31
326	Tumor suppressor genes and breast cancer. Radiation Oncology Investigations, 1999, 7, 55-65.	1.3	28
327	Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy. Journal of Clinical Oncology, 1999, 17, 460-460.	0.8	1,199
328	Do Calcium Channel Blockers Adversely Affect Hormonal Treatment of Prostate Cancer Through an Inhibition of Apoptosis?. Prostate Journal, 1999, 1, 43-48.	0.2	0
329	Cost-effectiveness of posttreatment surveillance after radiation therapy for early stage seminoma. , 1998, 82, 1126-1133.		20
330	Isoseparation curves: A mechanism for optimizing off-axis dose homogeneity of intact breast irradiation. Radiation Oncology Investigations, 1998, 6, 191-198.	1.3	3